News

One month into 2016, it’s clear that this will be a year of massive change for the managed care industry. Here are seven predictions for some of the key issues that will emerge, intensify, or be resolved by the end of this year.

Nearly 60% of new MA plans are sponsored by providers, according to new Avalere analysis.

As technology advances, it is transforming healthcare in ways never thought possible

N.Y. Gov. Andrew Cuomo proposes a budget provision that would call for capping prices on some drugs and requiring drug companies to provide information about their costs.

New technology is changing how payers, providers, and patients interact. Stay ahead of the curve by monitoring these technology changes.

When the House Committee on Oversight and Government Reform met on January 26, legislators took a closer look at price hikes from companies such as Valeant Pharmaceuticals and Turing Pharmaceuticals.

A common question facing healthcare executives is how to get started with population health management. Here are steps and strategies critical to success.

Another health insurer is facing a major healthcare data breach. Here’s how cybersecurity experts are reacting.

Eli Lilly & Company finally releases a high-dose insulin pen, which will help cut down on medication errors associated with the U-100 Humulin insulin pens.

To help ensure you are doing all you can to prevent a security breach, we asked the experts to weigh in. Here they identify four of the biggest mistakes health plans are making.

In this commentary, an industry insider shares his 2016 predictions for healthcare. Do you agree?

A new study of a pediatric ACO serving approximately 300,000 Medicaid-eligible children in Ohio evaluated whether financial incentives influence physician behavior.

For decades, administrative costs for health plans have stalled. Today’s healthcare market is full of opportunities to trim the fat.

The precision medicine uptake is not as fast as predicted in healthcare organizations, but academic medical centers are jumping on board faster than others.

FDA has approved secukinumab (Cosentyx, Novartis) for the treatment of adult patients with active ankylosing spondylitis and active psoriatic arthritis.

A new survey reveals what employers' medical plans are doing to rein in specialty drug cost and utilization.

It is young white males who are dying from drug overdoses in the U.S., according to a New York Times analysis of death certificates.

Abbott's Compounding Pharmacy in Berkeley, Calif., is voluntarily recalling all unexpired lots of sterile compounded products because of lack of sterility assurance.

We asked the Managed Healthcare Executive editorial advisory board to predict the biggest challenge healthcare executives will face this year. Here's what they said.

FDA has approved an expanded age indication for Hib vaccine (Hiberix, GlaxoSmithKine).

As the healthcare industry changes, health plan executives must master new skills.

While diabetes, particularly type 2, remains an epidemic, the number of new diagnoses has begun to slow. Here are some developments contributing to the decrease.

There is some good news for heart failure patients’ life expectancy, in a recent study published in the New England Journal of Medicine.

FDA advisers recommended approval of the first long-acting, subdermal buprenorphine implant (Probuphine, Titan Pharmaceuticals, Inc. and Braeburn Pharmaceuticals) for the maintenance treatment of opioid addiction.

New research: Hospitals risk millions from failure to provide consumer-friendly mobile apps. How to achieve exceptional consumer experience.

Broader exchange of ideas for diabetes health management and related programs may result in more efficient community-based programs with a wider impact.

Pharmaceutical companies are battling state legislation that would require state programs such as Medicaid to pay no more than other Federal government programs for drugs.

Independence reaches a deal with NantHealth to cover next-generation whole genome sequences for a variety of cancers.

Analysts ponder what Aetna’s leave from AHIP means for the industry and the powerhouse trade association.